Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology

European Journal of Heart Failure

Volumn 9, Issue 6-7, 2007, Pages 684-694

  Metra, Marco ^a   Ponikowski, Piotr ^b   Dickstein, Kenneth ^c   McMurray, John J V ^d   Gavazzi, Antonello ^e   Bergh, Claes Hakan ^f   Fraser, Alan G ^g   Jaarsma, Tiny ^h   Pitsis, Antonis ⁱ   Mohacsi, Paul ^j   Böhm, Michael ^k   Anker, Stefan ^l,m   Dargie, Henry ^d   Brutsaert, Dirk ⁿ   Komajda, Michel ^o  

^a UNIVERSITY OF BRESCIA   (Italy)

^b MILITARY HOSPITAL   (Poland)

^c UNIVERSITY OF BERGEN   (Norway)

^d WESTERN INFIRMARY   (United Kingdom)

^e OSPEDALI RIUNITI   (Italy)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g CARDIFF UNIVERSITY   (United Kingdom)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ St Luke's Hospital   (Greece)

^j UNIVERSITY OF BERN   (Switzerland)

^k SAARLAND UNIVERSITY   (Germany)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^m IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁿ UNIVERSITY OF ANTWERP   (Belgium)

^o PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

Heart failure; Prognosis; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE A1 RECEPTOR ANTAGONIST; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOSIMENDAN; LOOP DIURETIC AGENT; NITRATE; PERHEXILINE MALEATE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; TRIMETAZIDINE;

CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MEGADOSE; EUROPE; EXERCISE; FLUID RETENTION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE FILLING; HOSPITALIZATION; HUMAN; MEDICAL SOCIETY; OXYGEN CONSUMPTION; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

CHRONIC DISEASE; COMBINED MODALITY THERAPY; HEART FAILURE, CONGESTIVE; HUMANS; PROGNOSIS; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34248226980     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2007.04.003     Document Type: Review

References (83)

1. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
2. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article. A report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) 1116-1143
3. Abdulla J., Abildstrom S.Z., Christensen E., Kober L., and Torp-Pedersen C. A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction. Eur J Heart Fail 6 (2004) 927-935
4. Metra M., Giubbini R., Nodari S., Boldi E., Modena M.G., and Dei Cas L. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 102 (2000) 546-551
5. European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 19 (1998) 990-1003
6. Binanay C., Califf R.M., Hasselblad V., et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294 (2005) 1625-1633
7. Bittner V., Weiner D.H., Yusuf S., et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA 270 (1993) 1702-1707
8. Ingle L., Rigby A.S., Nabb S., Jones P.K., Clark A.L., and Cleland J.G. Clinical determinants of poor six-minute walk test performance in patients with left ventricular systolic dysfunction and no major structural heart disease. Eur J Heart Fail 8 (2006) 321-325
9. O'Neill J.O., Young J.B., Pothier C.E., and Lauer M.S. Peak oxygen consumption as a predictor of death in patients with heart failure receiving β-blockers. Circulation 111 (2005) 2313-2318
10. Mehra M.R., Kobashigawa J., Starling R., et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates-2006. J Heart Lung Transplant 25 (2006) 1024-1042
11. Adams Jr. K.F., and Zannad F. Clinical definition and epidemiology of advanced heart failure. Am Heart J 135 6 Pt 2 Su (1998) S204-S215
12. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
13. Goldstein S., Fagerberg B., Hjalmarson A., et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 38 (2001) 932-938
14. Lenzen M.J., Scholte op Reimer W.J.M., Boersma E., et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 25 (2004) 1214-1220
15. Aurigemma G.P. Diastolic heart failure-a common and lethal condition by any name. N Engl J Med 355 (2006) 308-310
16. Goodlin S.J., Hauptman P.J., Arnold R., et al. Consensus statement: palliative and supportive care in advanced heart failure. J Card Fail 10 (2004) 200-209
17. Nieminen M.S., Bohm M., Cowie M.R., et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 384-416
18. Cleland J.G., Swedberg K., Follath F., et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 24 (2003) 442-463
19. Rudiger A., Harjola V.-P., Muller A., et al. Acute heart failure: clinical presentation, one-year mortality and prognostic factors. Eur J Heart Fail 7 (2005) 662-670
20. Tavazzi L., Maggioni A.P., Lucci D., et al. Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J 27 (2006) 1207-1215
21. Zannad F., Mebazaa A., Juilliére Y., et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: the EFICA study. Eur J Heart Fail 8 7 (2006) 697-705
22. Petrie M.C., Caruana L., Berry C., and McMurray J.J. "Diastolic heart failure" or heart failure caused by subtle left ventricular systolic dysfunction?. Heart 87 (2002) 29-31
23. Vinereanu D., Nicolaides E., Tweddel A.C., and Fraser A.G. "Pure" diastolic dysfunction is associated with long-axis systolic dysfunction. Implications for the diagnosis and classification of heart failure. Eur J Heart Fail 7 (2005) 820-828
24. Pozzoli M., Traversi E., Cioffi G., Stenner R., Sanarico M., and Tavazzi L. Loading manipulations improve the prognostic value of Doppler evaluation of mitral flow in patients with chronic heart failure. Circulation 95 (1997) 1222-1230
25. Ommen S., Nishimura R.A., Appleton C.P., et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation 102 (2000) 1788-1794
26. Richards A.M., Troughton R., Lainchbury J., Doughty R., and Wright S. Guiding and monitoring of heart failure therapy with NT-ProBNP: concepts and clinical studies. J Card Fail 11 5 Suppl (2005) S34-S37
27. Shah M.R., Claise K.A., Bowers M.T., et al. Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. Am Heart J 150 (2005) 893-898
28. Working Group on Cardiac Rehabilitation and Exercise Physiology, and Working Group on Heart Failure of the European Society of Cardiology. Recommendations for exercise testing in chronic heart failure patients. Eur Heart J 22 (2001) 37-45
29. Chua T.P., Ponikowski P., Harrington D., et al. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol 29 (1997) 1585-1590
30. Kleber F.X., Vietzke G., Wernecke K.D., et al. Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation 101 (2000) 2803-2809
31. Corra U., Mezzani A., Bosimini E., and Giannuzzi P. Cardiopulmonary exercise testing and prognosis in chronic heart failure: a prognosticating algorithm for the individual patient. Chest 126 (2004) 942-950
32. Myers J., Gullestad L., Vagelos R., et al. Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure. Ann Intern Med 129 (1998) 286-293
33. Mancini D.M., Eisen H., Kussmaul W., Mull R., Edmunds Jr. L.H., and Wilson J.R. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 83 (1991) 778-786
34. Faggiano P., D'Aloia A., Gualeni A., Brentana L., and Dei Cas L. The 6 minute walking test in chronic heart failure: indications, interpretation and limitations from a review of the literature. Eur J Heart Fail 6 (2004) 687-691
35. Olsson L.G., Swedberg K., Clark A.L., Witte K.K., and Cleland J.G. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J 26 (2005) 778-793
36. Dickstein K., Gleim G., Snapinn S., James M., and Kjekshus J. The impact of morbid events on survival following hospitalisation for complicated myocardial infarction. Eur J Heart Fail 8 (2006) 74-80
37. Nieminen M.S., Brutsaert D., Dickstein K., et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 27 (2006) 2725-2736
38. Lee D.S., Austin P.C., Rouleau J.L., Liu P.P., Naimark D., and Tu J.V. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290 (2003) 2581-2587
39. Pocock S.J., Wang D., Pfeffer M.A., et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 27 (2006) 65-75
40. Levy W.C., Mozaffarian D., Linker D.T., et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113 (2006) 1424-1433
41. Gavazzi A., Ghio S., Scelsi L., et al. Response of the right ventricle to acute pulmonary vasodilation predicts the outcome in patients with advanced heart failure and pulmonary hypertension. Am Heart J 145 (2003) 310-316
42. Fonarow G.C., Adams Jr. K.F., Abraham W.T., Yancy C.W., Boscardin W.J., ADHERE Scientific Advisory Committee, Study Group, and and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293 (2005) 572-580
43. Komajda M., Follath F., Swedberg K., et al. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24 (2003) 464-474
44. Komajda M., Lapuerta P., Hermans N., et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 26 (2005) 1653-1659
45. Kittleson M., Hurwitz S., Shah M.R., et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol 41 (2003) 2029-2035
46. McMurray J., Cohen-Solal A., Dietz R., et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail 7 (2005) 710-721
47. Gattis W.A., O'Connor C.M., Gallup D.S., et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure (IMPACT-HF trial). J Am Coll Cardiol 43 (2004) 1534-1541
48. Metra M., Nodari S., D'Aloia A., et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 40 (2002) 1248-1258
49. Cohn J.N., Tognoni G., and for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
50. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
51. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
52. Costanzo M.R., Saltzberg M., O'Sullivan J., and Sobotka P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol 46 (2005) 2047-2051
53. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314 (1986) 1547-1552
54. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 (2004) 2049-2057
55. Ahmed A., Rich M.W., Love T.E., et al. Digoxin and reduction in mortality and hospitalisation in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27 (2006) 178-186
56. Thackray S., Easthaugh J., Freemantle N., and Cleland J.G. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail 4 (2002) 515-529
57. Cuffe M.S., Califf R.M., Adams Jr. K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1547
58. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). Eur Heart J 27 (2006) 1979-2030
59. Cleland J.G., Ghosh J., Freemantle N., et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 6 (2004) 501-508
60. Massie B.M. Aspirin use in chronic heart failure: what should we recommend to the practitioner?. J Am Coll Cardiol 46 (2005) 963-966
61. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004) 2140-2150
62. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 (2005) 1539-1549
63. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
64. Kadish A., Dyer A., Daubert J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 (2004) 2151-2158
65. Salukhe T.V., Dimopoulos K., Sutton R., Coats A.J., Piepoli M., and Francis D.P. Life-years gained from defibrillator implantation: markedly nonlinear increase during 3 years of follow-up and its implications. Circulation 109 (2004) 1848-1853
66. Feldman A.M., de Lissovoy G., Bristow M.R., et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 46 (2005) 2311-2321
67. Yao G., Freemantle N., Calvert M.J., Bryan S., Daubert J.C., and Cleland J.G. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 28 (2007) 42-51
68. Cleland J.G.F., Coletta A.P., Lammiman M., et al. Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur J Heart Fail 7 (2005) 1070-1075
69. Gheorghiade M., Orlandi C., Burnett J.C., et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 11 (2005) 260-269
70. Gottlieb S.S., Brater D.C., Thomas I., et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105 (2002) 1348-1353
71. Lee L., Campbell R., Scheuermann-Freestone M., et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112 (2005) 3280-3288
72. Fragasso G., Palloshi A., Puccetti P., et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 48 (2006) 992-998
73. Tavazzi L., Tognoni G., Franzosi M.G., et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 6 (2004) 635-641
74. Kjekshus J., Dunselman P., Blideskog M., et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 7 (2005) 1059-1069
75. Scottish Intercollegiate Guidelines Network - SIGN. 95 Management of chronic heart failure. A national clinical guideline. Available at http://www.sign.ac.uk/pdf/sign95.pdf.
76. McAlister F.A., Stewart S., Ferrua S., and McMurray J.J. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 44 (2004) 810-819
77. Stevenson L.W., and Rose E.A. Left ventricular assist devices: bridges to transplantation, recovery, and destination for whom?. Circulation 108 (2003) 3059-3063
78. Rose E.A., Gelijns A.C., Moskowitz A.J., et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345 (2001) 1435-1443
79. Elefteriades J.A., Tolis Jr. G., Levi E., et al. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol 22 (1993) 1411
80. Buckberg J.D. Questions and answers about the STICH trial: a different perspective. J Thorac Cardiovasc Surg 130 (2005) 245-249
81. Mann D.L. Cardiac remodeling as therapeutic target: treating heart failure with cardiac support devices. Heart Fail Rev 10 (2005) 93-94
82. Levenson J.W., McCarthy E.P., Lynn J., Davis R.B., and Phillips R.S. The last six months of life for patients with congestive heart failure. J Am Geriatr Soc 48 (2000) S101-S109
83. Freeborne N., Lynn J., and Desbiens N.A. Insights about dying from the SUPPORT project. The Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. J Am Geriatr Soc 48 (2000) S199-S205